Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 415

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 415
---
 |
| Conversion of Class B common stock to Class A common stock                  | ​ | ​ | ​                                   | $ |          — | ​ | ​ | ​ | ​                                   | $ |         690 | ​ | ​ |
| Remeasurement of Class A common stock subject to redemptionvalue            | ​ | ​ | ​                                   | $ |    205,382 | ​ | ​ | ​ | ​                                   | $ |     479,371 | ​ | ​ |
| Excise tax                                                                  | ​ | ​ | ​                                   | $ |     18,029 | ​ | ​ | ​ | ​                                   | $ |     103,587 | ​ | ​ |
| Income taxes paid                                                           | ​ | ​ | ​                                   | $ |    375,894 | ​ | ​ | ​ | ​                                   | $ |     193,845 | ​ | ​ |
| Recovery of excess redemptions – tax claim                                  | ​ | ​ | ​                                   | $ |    294,669 | ​ | ​ | ​ | ​                                   | $ |           — | ​ | ​ |
| Deemed contribution for extension deposit from related party                | ​ | ​ | ​                                   | $ |    117,669 | ​ | ​ | ​ | ​                                   | $ |           — | ​ | ​ |

The accompanying notes are an integral part of these unaudited condensed financial statements. F-5

TABLE OF CONTENTS

### IRIS ACQUISITION CORP

### NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

### NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
Iris Acquisition Corp (the “Company”) formally known as Tribe Capital Growth Corp I (name of the Company was changed on July 27, 2022), is a blank check company incorporated in Delaware on November 5, 2020. The Company was incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”).

As of September 30, 2024, the Company had not commenced any operations. All activity for the period from November 5, 2020 (inception) through September 30, 2024 relates to the Company’s formation and the initial public offering described below (the “IPO”), and subsequent to the IPO identifying a target company for a Business Combination. The Company will not